Study to Evaluate the Safety, PK, PD, and Efficacy of PRX-102 in Japanese Patients With Fabry Disease

Fabry Disease Clinical Trial

— RISE  

Official title:

A Multicenter Open-Label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Pegunigalsidase Alfa (PRX-102) in Japanese Patients With Fabry Disease (RISE)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05710692
• Other study ID #: CLI-06657AA2-01
• Status: Recruiting
• Phase: Phase 2/Phase 3
• Start date: August 1, 2023
• Est. completion date: March 2028

Study information

• Verified date: February 2024
• Source: Chiesi Farmaceutici S.p.A.
• Contact: Chiesi Clinical Trial
• Phone: +3905212791
• Email: clinicaltrials_info[@]chiesi.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of this study is to evaluate the safety and efficacy of pegunigalsidase alfa in Japanese patients (adults and adolescents) affected by Fabry disease. It is planned of a total of approximately 18-20 male and female Fabry disease patients between the ages of 13 and 60 years to be part of the study. The study is conducted in Japan.

Description:

Investigators are doing this study to find out if treatment with pegunigalsidase alfa will prevent or reduce the development of health problems caused by Fabry disease and thereby improve patients' health and quality of life.

pegunigalsidase alfa (PRX-102) is a drug made using genetic engineering techniques and manufactured using cultured tobacco cells. It is given by intravenous infusion every 2 weeks, at a dosage of 1 milligram per kilogram (mg/kg) of body weight.

The study consists of a main study that is divided into two stages, each of which will last one year, followed by an optional extension study. In the optional extension stage, the participants may receive PRX-102 intravenous infusion every 2 weeks, at a dosage of 1 milligram per kilogram (mg/kg) of body weight or every 4 weeks at a dosage of 2 milligrams per kilogram (mg/kg) of body weight.

There are three groups (cohorts) in this study, with adults enrolled in either Cohort A or B and adolescents in Cohort C. Whether an adult is assigned to Cohort A or Cohort B depends on their kidney function and treatment history.

This study will start with a screening visit of up to 4 weeks. It will be followed up by infusion visits every 2 weeks or 4 weeks. For subjects not continuing in the extension stage, a follow-up call is to be made 30 days after the last study drug infusion.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 18
• Est. completion date: March 2028
• Est. primary completion date: March 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion criteria (all subjects)

• Must have been born in Japan and have their biological parents and all 4 grandparents of Japanese descent

• A documented diagnosis of Fabry disease, as determined by the following:

• Males: Plasma and/or leukocyte alpha-galactosidase-A activity (by activity assay) that is = 5% of mean normal laboratory levels or, if the enzymatic activity is above the 5% limit but still under the normal level, a confirmed disease-causing mutation of the GLA gene

• Females: Historical genetic test results consistent with Fabry mutations or, in the case of novel mutations, a first-degree male relative with Fabry disease

• All subjects: At least one of the following characteristic features of Fabry disease:

neuropathic pain, cornea verticillata, and/or clustered angiokeratoma

• Estimated glomerular filtration rate (eGFR) at screening =40 mL/min/1.73 m2. For adults, this will be calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Creatinine equation (2009); and for adolescents, it will be calculated using the Creatinine Cystatin C-based Chronic Kidney Disease in Children (CKiD) equation.

• Clinical condition that in the opinion of the Investigator requires treatment with ERT

Additional inclusion criteria for subjects in Cohort A

• Aged =18 to =60 years

• Treatment with agalsidase beta for at least the last 12 months, with the dose stable (defined as having received at least 80% of the labelled dose) for at least the last 6 months

• Diagnosis of kidney impairment, defined as a linear slope of eGFR more negative or equal to -2 mL/min/1.73 m2/year. The historical eGFR slope will be calculated based on at least 3 serum creatinine values obtained over the past 9 to 24 months prior to screening, using the CKD-EPI Creatinine equation (2009). This criterion will be confirmed at screening by calculating the screening eGFR slope using historical and screening serum creatinine values. Both historical and screening eGFR slopes will be used for the diagnosis of kidney impairment.

Additional inclusion criterion for subjects in Cohort B

• Aged =18 to =60 years

Additional inclusion criteria for subjects in Cohort C

• Aged =13 to <18 years

• If they previously received or are currently receiving ERT treatment, the subjects must be negative for anti-drug antibodies for PRX-102

Exclusion Criteria:

• Administration of ERT for Fabry disease within 14 days before baseline, or chaperone therapy for Fabry disease within 3 days before baseline

• History of type I hypersensitivity reactions (anaphylactic or anaphylactoid life-threatening reaction) to other ERT treatment for Fabry disease or to any component of the study drug

• Cohort A only: eGFR value of >90 to =120 mL/min/1.73 m2 at screening and a historical eGFR value >120 mL/min/1.73 m2 in the past 9 to 24 months before screening, indicating absence of renal impairment

• Urine protein to creatinine ratio (UPCR) >0.5 g/g (0.5 mg/mg or 500 mg/g) if not treated with an ACE inhibitor or ARB

• Initiation of treatment, or a change in dose to ongoing treatment, with an angiotensin-converting-enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB) in the 4 weeks prior to screening.

• Currently taking another investigational drug for any condition

• Known non-pathogenic Fabry mutations

• History of renal dialysis or kidney transplantation

• History of acute kidney injury in the 12 months prior to screening, including specific kidney diseases (e.g., acute interstitial nephritis, acute glomerular and renal vasculitis); non-specific conditions (e.g., ischemia, toxic injury); as well as extrarenal pathology (e.g., prerenal azotemia, and acute postrenal obstructive nephropathy

• History of (or current) malignancy requiring treatment; the one exception is a prior history of resected basal cell carcinoma

• Severe cardiomyopathy or significant unstable cardiac disease within 6 months prior to screening

• A positive test for Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2) within 3 months prior to screening, using a validated molecular assay or validated antigen assay

• Females: Pregnant or lactating, or of childbearing potential with a fertile male partner and unwilling to use a highly reliable method of contraception from the informed consent signature until 30 days after the last study treatment

• Presence of any medical, emotional, behavioral, or psychological condition that in the judgment of the Investigator could interfere with the subject's compliance with the requirements of the study

Related Conditions & MeSH terms

• Fabry Disease

Intervention

Drug:
• PRX-102 1 mg/kg every 2 weeks
PRX-102 1 mg/kg every 2 weeks
• PRX-102 2 mg/kg every 4 weeks
PRX-102 2 mg/kg every 4 weeks

Locations

Country	Name	City	State
Japan	Juntendo University Hospital, 3-1-3 Hongo, Bunkyo-ku, Tokyo	Bunkyo-ku	Tokyo
Japan	Fukuoka University Chikushi Hospital	Chikushino	Fukuoka
Japan	Tokyo Jikei University Hospital	Minato-ku	Tokyo
Japan	Niigata University Medical & Dental Hospital	Niigata
Japan	University of the Ryukyu Hospital	Nishihara	Okinawa
Japan	Tohoku University Hospital	Sendai	Miyagi
Japan	Keio University Hospital	Shinjuku-ku	Tokyo
Japan	Osaka University Hospital	Suita	Osaka

Sponsors (2)

Lead Sponsor	Collaborator
Chiesi Farmaceutici S.p.A.	ICON plc

Country where clinical trial is conducted

Japan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Change in eGFR		12 Months, 24 Months and through study completion (an average of 4.5 years)
Other	Change in annualized eGFR slope		12 Months, 24 Months and through study completion (an average of 4.5 years)
Other	Change in urine albumin levels		12 Months, 24 Months and through study completion (an average of 4.5 years)
Other	Change in urine protein levels		12 Months, 24 Months and through study completion (an average of 4.5 years)
Other	Incidence of changes in echocardiogram results	Systolic and diastolic heart function and structure is assessed by ultrasound of the heart. Echocardiogram parameters include left ventricular mass index (LVMi), ejection fraction, fractional shortening, left ventricular mass, valve abnormalities and thickness.	12 Months, 24 Months and through study completion (an average of 4.5 years)
Other	Incidence of changes in Holter ECG		12 Months, 24 Months and through study completion (an average of 4.5 years)
Other	Change of cardiac biomarkers		12 Months, 24 Months and through study completion (an average of 4.5 years)
Other	Adults only: Response of the heart to external stress induced by exercise measured with Stress test (Bruce protocol)	Qualitative evaluation (yes/no) of symptoms (chest pain, shortness of breath, dizziness, palpitations, and other) and the overall impression: normal stress test (yes/no) will be summarized.; For overall impression only, a shift from baseline will be presented: normal stress test (yes / no).	12 Months, 24 Months and through study completion (an average of 4.5 years)
Other	Adults only: change of Cardiac MRI		12 Months, 24 Months and through study completion (an average of 4.5 years)
Other	Adults only: change of Brain MRI		12 Months, 24 Months and through study completion (an average of 4.5 years)
Other	Change in plasma level of Gb3 concentration (nM)		12 Months, 24 Months and through study completion (an average of 4.5 years)
Other	Change in plasma level of lyso-Gb3 (nM)		12 Months, 24 Months and through study completion (an average of 4.5 years)
Other	Change in urine level of lyso-Gb3 (nM)		12 Months, 24 Months and through study completion (an average of 4.5 years)
Other	Change from baseline of Mainz Severity Score Index (MSSI) scores	Domains (general, neurological, cardiovascular, renal dysfunction)	12 Months, 24 Months and at the end of study
Other	Incidence of change from baseline in the number of different pain medications		12 Months, 24 Months and at the end of study
Other	Incidence of Fabry Clinical Events	FCEs are classified into four categories: renal, cardiac, cerebrovascular and death due to non-cardiac reasons	12 Months, 24 Months and at the end of study
Other	Adults only: change in Gastrointestinal Symptom Rating Scale (GSRS) scores	To measure common symptoms of gastrointestinal disorders.	12 Months, 24 Months and at the end of study
Other	Adults only: change in Brief Pain Inventory - Short Form (BPI-SF) scores		12 Months, 24 Months and at the end of study
Other	Adults only: change of quality of life assessed using EQ-5D-5L questionnaire		12 Months, 24 Months and at the end of study
Other	Cohort C only: Change in Gastrointestinal Symptoms (PedsQL-GI) Questionnaire scores	To measure common symptoms of gastrointestinal disorders.	12 Months, 24 Months and at the end of study
Other	Cohort C only: change in Fabry-Specific Pediatric Health and Pain Questionnaire (FPHPQ) scores		12 Months, 24 Months and at the end of study
Other	Cohort C only: change in PedsQL Pediatric Pain Questionnaire (PedsQL-PPQ) scores		12 Months, 24 Months and at the end of study
Other	Cohort C only: change of quality of life assessed using EQ-5D-Y Questionnaire		12 Months, 24 Months and at the end of study
Primary	Incidence of Treatment Emergent Adverse Events (TEAEs)		12 Months, 24 Months and through study completion (an average of 4.5 years)
Primary	Incidence of Infusion Related Reactions (IRRs)		12 Months, 24 Months and through study completion (an average of 4.5 years)
Primary	Incidence of Injection site reactions (ISRs)		12 Months, 24 Months and through study completion (an average of 4.5 years)
Primary	Change of laboratory tests' results		12 Months, 24 Months and through study completion (an average of 4.5 years)
Primary	Change in in body weight in kilograms		12 Months, 24 Months and through study completion (an average of 4.5 years)
Primary	Change in height in centimeters		12 Months, 24 Months and through study completion (an average of 4.5 years)
Primary	Change in Tanner stage	Tanner Staging of Sexual Development will be used to assess sexual development (i.e. breast development (B1 to B5) and pubic hair development (Ph-1 to Ph-5) in females and pubic hair and genetical development (G1-G5) in males.	12 Months, 24 Months and through study completion (an average of 4.5 years)
Primary	Change from baseline of 12-lead ECG quantitative parameters: Mean Heart Rate, PR Interval, QRS Duration, QT Interval, QTc Interval, and ST Segment	Quantitative ECG parameters will be summarized by cohort and overall	12 Months, 24 Months and through study completion (an average of 4.5 years)
Primary	Incidence of treatment-emergent Anti-Drug Antibodies (ADAs)		12 Months, 24 Months and through study completion (an average of 4.5 years)
Primary	ADA status change from baseline		12 Months, 24 Months and through study completion (an average of 4.5 years)
Primary	Incidence of premedication use at each visit and change of infusion premedications from baseline		12 Months, 24 Months and through study completion (an average of 4.5 years)
Primary	Change from baseline of Maximum plasma concentration (Cmax), pharmacokinetic parameter		Assessments will be done over four two-week periods, starting at Baseline (Week 0), V7 (Week 12), V14 (Week 26), and V27 (Week 52)
Primary	Change from baseline of Time to maximum plasma concentration (tmax), pharmacokinetic parameter		Assessments will be done over four two-week periods, starting at Baseline (Week 0), V7 (Week 12), V14 (Week 26), and V27 (Week 52)
Primary	Change from baseline of Area under the plasma concentration-time curve from time 0 to time t (AUC0 t), pharmacokinetic parameter		Assessments will be done over four two-week periods, starting at Baseline (Week 0), V7 (Week 12), V14 (Week 26), and V27 (Week 52)
Primary	Change from baseline of Area under the curve from time 0 to 2 weeks (AUC0-2wk), pharmacokinetic parameter		Assessments will be done over four two-week periods, starting at Baseline (Week 0), V7 (Week 12), V14 (Week 26), and V27 (Week 52)
Primary	Change from baseline of Area under the curve from time 0 to infinity (AUC0-8), pharmacokinetic parameter		Assessments will be done over four two-week periods, starting at Baseline (Week 0), V7 (Week 12), V14 (Week 26), and V27 (Week 52)
Primary	Change from baseline of Terminal half-life (t1/2), pharmacokinetic parameter		Assessments will be done over four two-week periods, starting at Baseline (Week 0), V7 (Week 12), V14 (Week 26), and V27 (Week 52)
Primary	Change from baseline of Area under the curve over a dosing interval (AUCt), pharmacokinetic parameter		Assessments will be done over four two-week periods, starting at Baseline (Week 0), V7 (Week 12), V14 (Week 26), and V27 (Week 52)
Primary	Change from baseline of Observed drug concentration at the end of the dosing interval (Ct), pharmacokinetic parameter		Assessments will be done over four two-week periods, starting at Baseline (Week 0), V7 (Week 12), V14 (Week 26), and V27 (Week 52)
Primary	Change from baseline of Clearance (Cl), pharmacokinetic parameter		Assessments will be done over four two-week periods, starting at Baseline (Week 0), V7 (Week 12), V14 (Week 26), and V27 (Week 52)
Primary	Change from baseline of Volume of distribution (Vz), pharmacokinetic parameters		Assessments will be done over four two-week periods, starting at Baseline (Week 0), V7 (Week 12), V14 (Week 26), and V27 (Week 52)